Jazz Pharmaceuticals (JAZZ) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Is JAZZ or RPRX more profitable?

Royalty Pharma has a net margin of 37.94% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	11.60%	29.30%	9.72%
Royalty Pharma	37.94%	24.40%	14.01%

Do insiders & institutionals have more ownership in JAZZ or RPRX?

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are held by institutional investors. 4.2% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 18.9% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more risk and volatility, JAZZ or RPRX?

Jazz Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Does the MarketBeat Community believe in JAZZ or RPRX?

Jazz Pharmaceuticals received 812 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 80.87% of users gave Jazz Pharmaceuticals an outperform vote while only 67.99% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Jazz Pharmaceuticals	Outperform Votes 1137 80.87%	Underperform Votes 269 19.13%
Royalty Pharma	Outperform Votes 325 67.99%	Underperform Votes 153 32.01%

Which has higher valuation and earnings, JAZZ or RPRX?

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.07B	1.77	$414.83M	$8.79	13.33
Royalty Pharma	$2.26B	8.27	$858.98M	$1.45	22.40

Does the media refer more to JAZZ or RPRX?

In the previous week, Jazz Pharmaceuticals had 12 more articles in the media than Royalty Pharma. MarketBeat recorded 23 mentions for Jazz Pharmaceuticals and 11 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.38 beat Jazz Pharmaceuticals' score of 0.87 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	12 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend JAZZ or RPRX?

Jazz Pharmaceuticals presently has a consensus target price of $187.71, indicating a potential upside of 60.19%. Royalty Pharma has a consensus target price of $42.50, indicating a potential upside of 30.85%. Given Jazz Pharmaceuticals' higher possible upside, research analysts plainly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 10 of the 19 factors compared between the two stocks.